The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (T2DM). Also, the compounds may be useful in the treatment of obesity.

This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.

This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.

This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.

This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.

This invention provides compositions comprising a protein and an omega-3 fatty acid, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.

This invention provides compositions comprising a protein and an omega-3 fatty acid, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.

Methods and compositions promote weight loss in mammals, such as in humans and/or animals, such as, for example, pets. Specifically, the methods and compositions herein promote weight loss due to the production of appetite-suppressing gut hormones, increased metabolism, reduced fat and carbohydrate absorption, and reduced fat deposition through the synergistic combination of fibers and botanical extracts. Food products comprising the compositions herein provide a natural and effective means of controlling appetite and managing weight.

Methods and compositions promote weight loss in mammals, such as in humans and/or animals, such as, for example, pets. Specifically, the methods and compositions herein promote weight loss due to the production of appetite-suppressing gut hormones, increased metabolism, reduced fat and carbohydrate absorption, and reduced fat deposition through the synergistic combination of fibers and botanical extracts. Food products comprising the compositions herein provide a natural and effective means of controlling appetite and managing weight.

Described herein are methods and compositions for treating diabetes mellitus, concerning oral pharmaceutical compositions comprising insulin in combination with a GLP-1 analogue.